How Is NK Cell Therapy Safety Managed in Japan? A Guide for International Patients

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are considering NK cell therapy in Japan, one of the first questions is usually about safety. Who oversees the treatment? What happens to your cells? What side effects are possible? This article explains, in general terms, how safety is approached for NK cell therapy in Japan and which questions are worth raising with a doctor at Grand Green Osaka Umekita Clinic in Osaka (Umeda) before you decide anything.

The short version is this: NK cell therapy is a self-pay (non-insured) treatment that is provided under Japan’s regulatory system for regenerative medicine. It uses your own cells, which is one reason serious side effects have rarely been reported, but no treatment is free of risk and no outcome can be guaranteed. Whether it is suitable for you can only be judged by a doctor after a consultation.

What NK Cell Therapy Involves

NK (natural killer) cells are a type of lymphocyte that circulates in the blood. They are part of the innate immune system and are known for their ability to detect and attack abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. NK cell activity has been reported to decline with age, stress, and the effects of cancer itself.

In NK cell therapy, NK cells are obtained from an ordinary blood draw, activated and expanded at a specialized cell processing facility, and then returned to your body by intravenous infusion. The aim is to reinforce immune function by returning NK cells that are greater in number and higher in activity. It is important to understand this as an aim of the therapy, not as a promise of results.

Why Using Your Own Cells Matters for Safety

The therapy is autologous, meaning the cells come from you and return to you. Because your own cells are used, the risk of rejection is considered low, and serious side effects have rarely been reported. This is one of the main reasons many patients see NK cell therapy as a gentler option compared with some other treatments.

That said, a low risk of rejection is not the same as no risk. Temporary fever or fatigue may occur after an infusion. Any intravenous procedure also carries general considerations, such as discomfort at the needle site. A doctor should explain what you might experience, how long it could last, and what to do if symptoms appear after you leave the clinic.

How Japan’s Regenerative Medicine Framework Fits In

In Japan, cell-based treatments of this kind are provided under the Act on the Safety of Regenerative Medicine. Under this framework, a medical institution submits a treatment plan for each type of therapy, and that plan is reviewed by a certified committee and submitted to the Ministry of Health, Labour and Welfare before treatment can be offered. Cell processing is also expected to be carried out at facilities that meet defined standards.

For international patients, this is useful context. It means the therapy sits inside a regulated system with expectations about documentation, cell handling, and reporting of health problems. It does not mean that the therapy is covered by public insurance, and it does not mean that effectiveness has been established for every cancer type. Regulation is about how treatment is provided safely and transparently, not a guarantee of benefit.

Because NK cell therapy is a self-pay treatment, fees, the number of infusions, the treatment period, and the risks and side effects are all things you should confirm directly with the doctor and in the clinic’s written explanation before you agree to start.

Using NK Cell Therapy Alongside Standard Cancer Treatment

NK cell therapy is not presented as a replacement for surgery, chemotherapy, or radiation therapy. It is generally considered an option that can be used alongside these treatments, with timing coordinated by your doctors. Standard treatment recommended by your oncology team remains the foundation of care for most patients, and you should not stop or delay it on the basis of an internet article.

If you are already being treated at a hospital in your home country or in Japan, safety is partly a matter of coordination. A doctor in Osaka can explain how the timing of an infusion might relate to your current treatment, and the clinic can coordinate with the medical institution providing your standard care. Bringing your latest medical summary, medication list, and test results to the first consultation makes this conversation far more useful.

Questions to Ask Before You Decide

A clear consultation is the best safety tool a patient has. The following questions are a practical starting point, and you are free to ask them in any order.

• Is my situation suitable for NK cell therapy, and are there reasons it might not be advisable for me?
• What side effects are possible, how are they monitored, and who can I contact after I return to my hotel or home country?
• What are the total costs, how many infusions are proposed, and over what period?
• What are the limits of this therapy, and what is known and not known about its effect on my type of cancer?
• How will the clinic communicate with my home oncologist about my treatment?

Language can also affect safety, because informed consent only works if you truly understand what is being explained. Grand Green Osaka Umekita Clinic provides information pages for international patients in several languages, and you can use them to prepare your questions before your visit. If something is unclear, ask for it to be explained again or written down.

Putting Safety in Perspective

NK cell therapy in Japan combines two safety-related features: the use of your own cells and a regulatory framework that governs how the treatment is planned, prepared, and provided. Together, these explain why it is generally described as a treatment with few reported serious side effects. They do not remove uncertainty about how well it may work for any individual.

If you are weighing this option, the sensible next step is a consultation. A doctor can review your medical history, explain the benefits and limits, and discuss costs, risks, and side effects in plain language. You can then take that information back to your own oncology team and decide at your own pace. For the full details of the therapy, please see the NK cell therapy page on this website and consult a doctor before making any decision.

• Your own cellsAutologous, low rejection risk
• Regulated in JapanRegenerative medicine framework
• Know the side effectsTemporary fever or fatigue
• Talk to your doctorsAsk before you decide

This diagram is a conceptual summary of the article

References

• PubMed: Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. (2026)
• PubMed: Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. (2020)
• PubMed: CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. (2023)
• PubMed: A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. (2022)
• PubMed: Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. (2025)
• PMC: Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. (2013)
• PMC: Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. (2022)
• PMC: Purification and antibody-free ex-vivo expansion of peripheral blood-derived autologous natural killer cells: A Malaysian case series on patient safety and tolerability. (2026)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.